| Nusinersen in adults with 5q spinal muscular atrophy: a non-interventional, multicentre, observational cohort study T Hagenacker, CD Wurster, R Günther, O Schreiber-Katz, A Osmanovic, ... The Lancet Neurology 19 (4), 317-325, 2020 | 293 | 2020 |
| Safety and effectiveness of long-term intravenous administration of edaravone for treatment of patients with amyotrophic lateral sclerosis S Witzel, A Maier, R Steinbach, J Grosskreutz, JC Koch, A Sarikidi, S Petri, ... JAMA neurology 79 (2), 121-130, 2022 | 148 | 2022 |
| ROCK-ALS: protocol for a randomized, placebo-controlled, double-blind phase IIa trial of safety, tolerability and efficacy of the rho kinase (ROCK) inhibitor fasudil in … P Lingor, M Weber, W Camu, T Friede, R Hilgers, A Leha, C Neuwirth, ... Frontiers in neurology 10, 293, 2019 | 71 | 2019 |
| Screening for lipoprotein receptor-related protein 4-, agrin-, and titin-antibodies and exploring the autoimmune spectrum in myasthenia gravis I Cordts, N Bodart, K Hartmann, K Karagiorgou, JS Tzartos, L Mei, ... Journal of neurology 264, 1193-1203, 2017 | 54 | 2017 |
| Serum creatine kinase and creatinine in adult spinal muscular atrophy under nusinersen treatment M Freigang, CD Wurster, T Hagenacker, B Stolte, M Weiler, C Kamm, ... Annals of clinical and translational neurology 8 (5), 1049-1063, 2021 | 50 | 2021 |
| Effect of nusinersen on motor, respiratory and bulbar function in early-onset spinal muscular atrophy A Pechmann, M Behrens, K Dörnbrack, A Tassoni, S Stein, S Vogt, ... Brain 146 (2), 668-677, 2023 | 46 | 2023 |
| Informal caregiving in amyotrophic lateral sclerosis (ALS): a high caregiver burden and drastic consequences on caregivers’ lives P Schischlevskij, I Cordts, R Günther, B Stolte, D Zeller, C Schröter, ... Brain sciences 11 (6), 748, 2021 | 44 | 2021 |
| Bi-allelic HPDL variants cause a neurodegenerative disease ranging from neonatal encephalopathy to adolescent-onset spastic paraplegia RA Husain, M Grimmel, M Wagner, JC Hennings, C Marx, RG Feichtinger, ... The American Journal of Human Genetics 107 (2), 364-373, 2020 | 44 | 2020 |
| Intrathecal nusinersen administration in adult spinal muscular atrophy patients with complex spinal anatomy I Cordts, P Lingor, B Friedrich, V Pernpeintner, C Zimmer, M Deschauer, ... Therapeutic advances in neurological disorders 13, 1756286419887616, 2020 | 36 | 2020 |
| ALSFRS-R-SE: an adapted, annotated, and self-explanatory version of the revised amyotrophic lateral sclerosis functional rating scale A Maier, M Boentert, P Reilich, S Witzel, S Petri, J Großkreutz, ... Neurological research and practice 4 (1), 60, 2022 | 29 | 2022 |
| A nation-wide, multi-center study on the quality of life of ALS patients in Germany T Peseschkian, I Cordts, R Günther, B Stolte, D Zeller, C Schröter, ... Brain Sciences 11 (3), 372, 2021 | 29 | 2021 |
| The UK Myotonic Dystrophy Patient Registry: facilitating and accelerating clinical research L Wood, I Cordts, A Atalaia, C Marini-Bettolo, P Maddison, M Phillips, ... Journal of neurology 264, 979-988, 2017 | 29 | 2017 |
| Routine cerebrospinal fluid (CSF) parameters in patients with spinal muscular atrophy (SMA) treated with nusinersen CD Wurster, JC Koch, I Cordts, J Dreyhaupt, M Otto, Z Uzelac, S Witzel, ... Frontiers in neurology 10, 1179, 2019 | 26 | 2019 |
| Improved upper limb function in non-ambulant children with SMA type 2 and 3 during nusinersen treatment: a prospective 3-years SMArtCARE registry study A Pechmann, M Behrens, K Dörnbrack, A Tassoni, F Wenzel, S Stein, ... Orphanet Journal of Rare Diseases 17 (1), 384, 2022 | 25 | 2022 |
| Successful treatment with azacitidine in VEXAS syndrome with prominent myofasciitis I Cordts, JS Hecker, D Gauck, J Park, J Härtl, R Günthner, A Hammitzsch, ... Rheumatology 61 (5), e117-e119, 2022 | 25 | 2022 |
| MYO9A deficiency in motor neurons is associated with reduced neuromuscular agrin secretion E O’Connor, V Phan, I Cordts, G Cairns, S Hettwer, D Cox, H Lochmüller, ... Human Molecular Genetics 27 (8), 1434-1446, 2018 | 25 | 2018 |
| Performance of serum neurofilament light chain in a wide spectrum of clinical courses of amyotrophic lateral sclerosis—a cross‐sectional multicenter study T Meyer, E Salkic, T Grehl, U Weyen, D Kettemann, P Weydt, R Günther, ... European Journal of Neurology 30 (6), 1600-1610, 2023 | 23 | 2023 |
| Improvements in walking distance during nusinersen treatment–a prospective 3-year SMArtCARE registry study A Pechmann, M Behrens, K Dörnbrack, A Tassoni, F Wenzel, S Stein, ... Journal of Neuromuscular Diseases 10 (1), 29-40, 2023 | 19 | 2023 |
| Spectrum and frequency of genetic variants in sporadic amyotrophic lateral sclerosis WP Ruf, M Boros, A Freischmidt, D Brenner, V Grozdanov, J de Meirelles, ... Brain Communications 5 (3), fcad152, 2023 | 19 | 2023 |
| Patient-reported prevalence of non-motor symptoms is low in adult patients suffering from 5q spinal muscular atrophy R Günther, CD Wurster, I Cordts, JC Koch, C Kamm, D Petzold, E Aust, ... Frontiers in neurology 10, 1098, 2019 | 18 | 2019 |